Fatigue Reduction Diet for Lymphoma Survivors
Trial Summary
What is the purpose of this trial?
In this study the investigators are proposing to evaluate the efficacy, sustainability, and mechanisms of 3 months of individualized counseling of the FRD delivered by registered dietitians, over 8 sessions by phone/video conferencing on fatigue, quality of life, and associated symptoms in persistently fatigued lymphoma cancer survivors compared to 3 months of individualized counseling of the attention control (matched for time and frequency of interactions with the FRD) the General Health Curriculum (GHC). The investigators will randomize and follow 68 lymphoma cancer survivors; accounting for a \~10% drop out rate to achieve a target of 60 patients that will complete the study. The investigators hypothesize that persistently fatigued lymphoma cancer survivors will experience improvements in fatigue, quality of life, and symptoms commonly associated with fatigue, which are then maintained at 15-months post-enrollment; and decreased CRP and alterations in inflammation-associated DNA methylation consistent with reduced inflammation from following the FRD as compared to the GHC.
Will I have to stop taking my current medications?
The trial requires that you do not change your current medications, supplements, or therapies during the study. If you have recently started, stopped, or changed any chronic medications, you may not be eligible to participate.
What data supports the effectiveness of the Fatigue Reduction Diet treatment for reducing fatigue in lymphoma survivors?
A pilot study showed that the Fatigue Reduction Diet (FRD) improved diet quality and significantly reduced fatigue in lymphoma survivors over a 12-week period. Participants who followed the diet, which included specific fruits, vegetables, whole grains, and omega-3 rich foods, reported less fatigue by the end of the study.12345
Is the Fatigue Reduction Diet safe for humans?
The Fatigue Reduction Diet (FRD) has been tested in a pilot study with lymphoma survivors and was found to be feasible and acceptable, with participants attending all sessions and completing the intervention without reported safety issues. Additionally, similar dietary interventions aimed at reducing cancer-related fatigue have been well-tolerated by cancer survivors, suggesting that such diets are generally safe for humans.12356
How does the Fatigue Reduction Diet treatment differ from other treatments for lymphoma survivors?
The Fatigue Reduction Diet (FRD) is unique because it focuses on improving diet quality through specific food choices like fruits, vegetables, whole grains, and omega-3 rich foods, which are believed to reduce cancer-related fatigue by addressing nutritional deficiencies and inflammation. Unlike other treatments, FRD is a remote dietary intervention involving personalized sessions with a dietitian, making it accessible and tailored to individual needs.12357
Research Team
Suzie Zick
Principal Investigator
University of Michigan Rogel Cancer Center
Eligibility Criteria
This trial is for men and women over 18 who finished their primary lymphoma treatments between 6 months to 2 years ago, have no signs of disease getting worse, eat less than 5.5 servings of fruits and veggies a day, were treated with specific chemo regimens (R-CHOP or R-EPOCH), suffer from persistent fatigue since their diagnosis, and can use email for study questionnaires.Inclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
3 months of individualized counseling of the Fatigue Reduction Diet (FRD) or General Health Curriculum (GHC) delivered by registered dietitians over 8 sessions by phone/video conferencing
Follow-up
Participants are monitored for improvements in fatigue, quality of life, and associated symptoms, maintained at 15-months post-enrollment
Treatment Details
Interventions
- Fatigue Reduction Diet (Behavioural Intervention)
- General Health Curriculum (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Michigan Rogel Cancer Center
Lead Sponsor
Marschall S. Runge
University of Michigan Rogel Cancer Center
Chief Executive Officer since 2015
MD, PhD
Eric R. Fearon
University of Michigan Rogel Cancer Center
Chief Medical Officer since 2016
MD, PhD
American Institute for Cancer Research
Collaborator